Navigation Links
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

s.prop15='79403392';s.tl(this,'o','ExternalLink');" target='_blank' href="http://content.nejm.org/cgi/content/full/348/26/2609">SUMMIT and APEX clinical trials that led to the FDA approval of bortezomib (Velcade®) for the treatment of multiple myeloma. More recently, he served as clinical trials core chair of the Multiple Myeloma Research Consortium, completing 5 years of service in the role this year. Dr. Anderson serves as Chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee and chairs the scientific advisory board for the Multiple Myeloma Research Foundation. In addition to playing an integral role in the development and approval of bortezomib, Drs. Richardson and Anderson led both preclinical and early phase clinical trials for the immunomodulatory drug lenalidomide (Revlimid®), leading to its FDA approval in 2007 .

Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are very excited to be initiating the first pivotal program, under an SPA, for perifosine, a novel, oral inhibitor of a critical target in cancer development and progression. This study initiation represents a major milestone for the Company and demonstrates the capabilities of our internal clinical team." Mr. Bentsur add
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
(Date:1/15/2014)... ANTONIO , Jan. 15, 2014 Most osteoporosis ... according to a recent online survey* sponsored by Mission ... among the National Osteoporosis Foundation online support community, revealed ... take medication that comes in a form other than ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
(Date:7/12/2014)... Demand Response Management Systems is a crucial peak ... imbalance between energy supply and demand. With the help ... (due to increasing pressure on the grid) and replaced ... residential appliances and thermostats for load reduction. , ... and with government mandates and benefits for energy efficiency ...
(Date:7/12/2014)... 12, 2014 Tylenol lawsuits ( ... move forward in the federal multidistrict litigation underway ... Bernstein Liebhard LLP reports. According to a filing ... F. Stengel has ordered the deposition of a ... found that the witness’s testimony concerning the marketing ...
(Date:7/12/2014)... (HealthDay News) -- Burn injuries increase in the summer as ... burn experts. Among those most vulnerable to these seasonal fire ... and often get burned by putting their hands on the ... the burn unit at Loyola University Medical Center in Maywood, ... adage of ,When you play with fire, you get burned, ...
(Date:7/12/2014)... July 12, 2014 “After my mom’s stroke, she ... a stroke and loss the use of his left side. Eating ... a way to help people like them enjoy eating again,” said ... prototype for the PATRICIA CAROL HALL PLATE (P C H PLATE). ... a more ergonomic way to eat for individuals who suffer from ...
(Date:7/12/2014)... July 12, 2014 With prom shopping ... manufacturer and retailer, is ready to showcase its new ... new collection of evening dresses in its online shop. ... 67% off) for these elegant gowns. According to the ... end on July 26, 2014. , He says, ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2
... clinical trial of the experimental drug dimebon (latrepirdine) in people ... cognition. That is the conclusion of a study published ... "This is the first clinical trial that has focused ... disease," said University of Rochester Medical Center neurologist Karl Kieburtz, ...
... with use, but other factors may contribute, experts say , ... treat glaucoma appear to outlive those who don,t treat the ... reduced risk for premature death stems from the glaucoma drugs ... access to health care remains unclear. , Use of glaucoma ...
... residue may give rise to new pollutants indoors, chemists ... smoke residue found on indoor surfaces -- so-called "third-hand ... new, potentially cancer-causing substances, research suggests. , Details about ... what health concerns it might create remain unclear, however, ...
... BOSTON , Feb. 8 The National Patient ... on March 7, 2010 , in a concerted effort ... of health care, and strengthen alliances between patients, families and ... During the week, participating hospitals and healthcare systems will plan ...
... , Feb. 8 Independence Blue Cross (IBC) today ... newly created role of senior vice president of marketing services. He ... executive, Linda M. Taylor . , In this new ... care consumers better manage their care and will also head product ...
... , Feb. 8 SpectraCell Laboratories announced that ... D.C. to its scientific staff as Director of Clinical Nutrition ... national basis and consult with clients on the implementation of ... is a long-time client of SpectraCell, using their micronutrient testing ...
Cached Medicine News:Health News:Drug shows promise for Huntington's disease 2Health News:Glaucoma Drugs May Play Role in Longer Life 2Health News:Glaucoma Drugs May Play Role in Longer Life 3Health News:'Third-Hand Smoke' Could Be Troublesome, Too 2Health News:'Third-Hand Smoke' Could Be Troublesome, Too 3Health News:National Patient Safety Foundation Leads Nationwide Effort to Promote Patient Safety 2Health News:Independence Blue Cross Names John Janney to Newly Created Position: Senior Vice President Marketing Services 2Health News:Independence Blue Cross Names John Janney to Newly Created Position: Senior Vice President Marketing Services 3Health News:Dr. Ron Grabowski Named Director of Clinical Nutrition and Education for SpectraCell Laboratories 2Health News:Dr. Ron Grabowski Named Director of Clinical Nutrition and Education for SpectraCell Laboratories 3
InterVascular HemaPatch product line offers the vascular surgeon a range of collagen coated patches in a range of larger sizes angioplasty, or profundaplasty procedures without suture hole bleeding. ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
The D-Stat Radial hemostat band utilizes a compression band together with the active haemostatic material of the D-Stat to control surface bleeding....
Medicine Products: